This is a multicenter phase IIa study to evaluate the efficacy and tolerability of
ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with recurrent
or metastatic HER-2 negative breast cancer, that are suitable for treatment with a taxane as
1st-3rd line of therapy.